UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of
Foreign Private Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
Dated September 30, 2019
Commission File Number 001-37518
Benitec Biopharma Limited
(Translation of registrant’s name into English)
Level 14, William Street
Melbourne 3000, VIC, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file
number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable
This report on Form 6-K is incorporated by reference in the Prospectus Supplement of Benitec Biopharma Limited filed with the U.S. Securities and Exchange Commission (“SEC”) on September 30, 2019, and shall be
deemed to be a part thereof from the date on which this report is furnished to the SEC, to the extent not superseded by documents or reports subsequently filed or furnished.